World Health Organization Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
April 10, 2014
This article was reported by NAM aidsmap.
NAM aidsmap reported that the World Health Organization (WHO) recently released new hepatitis C treatment guidelines. The guidelines call for global usage of Gilead's new drug, Sovaldi, while encouraging a price reduction of the $84,000-per-treatment medication. The drug must be used in combination with other medication, depending on genotype.
Gilead recently negotiated a price reduction of Sovaldi with Egypt to provide the drug at a price of $1,200 per 12-week course. It currently is seeking voluntary licenses to allow pharmaceutical companies in India to produce and distribute Sovaldi to 60 counties in Africa and Asia for $2,000-per-treatment-course. "I hope these guidelines will help to promote a reduction in price and thereby an increase in access," said Stefan Wiktor, head of the WHO hepatitis program. WHO completed its guidelines before Gilead negotiated pricing in countries outside the United States.View Full Article
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)